Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/13/2845293/0/en/BioCardia-and-StemCardia-Announce-Biotherapeutic-Delivery-Partnership.html
https://www.globenewswire.com//news-release/2024/03/12/2844385/0/en/BioCardia-Announces-CMS-Approval-of-Coverage-for-CardiAMP-Cell-Therapy-Confirmatory-Phase-III-Heart-Failure-Study.html
https://www.globenewswire.com//news-release/2024/03/04/2839508/0/en/BioCardia-Reports-Positive-Interim-Results-from-Phase-III-CardiAMP-Cell-Therapy-Heart-Failure-Trial-with-Compelling-Data-in-Subgroup-with-Elevated-NTproBNP-Biomarker-for-Heart-Fail.html
https://www.globenewswire.com//news-release/2024/02/08/2825876/0/en/BioCardia-Announces-Activation-of-CardiAMP-Heart-Failure-II-Phase-3-Pivotal-Study-Recently-Approved-by-FDA.html
https://www.globenewswire.com/news-release/2024/01/31/2820965/0/en/BioCardia-Announces-Two-Scientific-Abstracts-Have-Been-Accepted-at-the-2024-Technology-and-Heart-Failure-Therapeutics-Conference.html
https://www.globenewswire.com//news-release/2024/01/03/2803155/0/en/BioCardia-Biotherapeutic-Delivery-and-Morph-Access-Innovations-Business-Development-Update-for-Shareholders.html
https://www.globenewswire.com//news-release/2023/12/19/2798416/0/en/BioCardia-Doses-First-Patient-in-CardiALLO-Phase-I-II-Clinical-Trial-of-BCDA-03-Allogeneic-Mesenchymal-Stem-Cells-for-the-Treatment-of-Ischemic-Heart-Failure-of-Reduced-Ejection-Fr.html
https://www.globenewswire.com//news-release/2023/12/18/2797714/0/en/BioCardia-Announces-Expected-CardiAMP-Heart-Failure-Japan-Approval-Timeline-Based-on-Pharmaceutical-and-Medical-Device-Agency-Consultation-Minutes.html
https://www.globenewswire.com//news-release/2023/11/29/2787607/0/en/BioCardia-Shares-Update-from-Japan-PMDA-Consultation-on-CardiAMP-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure-Foreign-Data-Expected-to-be-Sufficient-for-Product-Approval.html
https://www.globenewswire.com//news-release/2023/11/16/2782140/0/en/BioCardia-Announces-1-3-Million-Registered-Direct-Offering-of-Common-Stock-Priced-At-the-Market-under-Nasdaq-Rules.html